Nanocomplex exhibits anti-tumor efficacy and induces apoptosis in cancer cells, suggesting potential for synergistic therapy.
Due to the intricate nature of tumors, developing multidrug delivery system to enhance synergistic therapy for tumors is urgently needed. Herein, we present a carrier-free nanocomplex (DHT NC@SF MPN), consisting of dihydrotanshinone-1 nanocrystals (DHT NC) combined with silybin-ferric metal-phenolic network coatings (SF MPN), for multidrug self-delivery and chemo/chemodynamic synergistic cancer therapy. The generated nanocomplex (DHT NC@SF MPN) was completely composed of three therapeutic ingredients: DHT (56.08 %), Sil (41.88 %), and Fe(III) (2.01 %) without incorporation of any nano-materials. It displayed spherical core-shell structure with particle size 262 nm and acid responding drug release. The nanocomplex could be efficiently uptaken by HGC-27 tumor cells through the lipid raft/caveolin mediated pathway. It exhibited stronger tumor cell proliferation inhibition, migration inhibition, cell apoptosis and ferroptosis compared with free drugs. On tumor bearing mice, it showed comparable anti-tumor efficacy with the commercial paclitaxel liposome while systemic toxicity was negligible. Therefore, the facile nanocarrier-free multidrug self-delivery nanoplatform shed light on developing advanced nanomedicine for tumor synergistic therapy.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: